Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HK2 | P52789 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291527 | 0.86 | L3MBTL1 (0.56) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL10024168 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL457103 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL16256685 | 0.79 | EPHX1 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3071849 | 0.78 | L3MBTL1 (0.63) | L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13139940 | 0.77 | TAS1R3 (0.63) | L3MBTL1TAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL3101236 | 0.77 | L3MBTL1 (0.50) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL13156516 | 0.77 | L3MBTL1 (0.50) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL9082219 | 0.77 | L3MBTL1 (0.44) | L3MBTL1ALOX5HK1HK2TAS1R3 | |
| SCHEMBL3080624 | 0.76 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895732-B2 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895732-B2 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| EP-2411374-B1 | PROCESS FOR SEPARATING ENANTIOMERS OF 3,6-DIHYDRO-1,3,5-TRIAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-20120016121-A1 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016121-A1 | Process for the separation of enantiomers of 3,6-dihydro-1,3,5-triazine derivatives | RER1, ABCB11, SLC67A1 | L3MBTL1 3933/4885ALOX5 2584/4885HK1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.